Effect of silymarin for the prevention of drug-induced liver injury in tuberculosis patients
Abstract
To evaluate the effect of silymarin for the prevention of antituberculosis drug-induced liver injury 307 new tuberculosis patients were enrolled to the retrospective cohort study. The patients of silymarin group (n = 204) received silymarin in a dose of 105 mg per day from the start of anti-tuberculosis treatment; patients of control group (n = 103) received only anti-tuberculosis drugs. The follow-up period were equal to the duration of intensive phase of anti-tuberculosis treatment. Drug-induced liver injury was registered in 20.1% (41/204) and 33.0% (34/103) in silymarin and control groups, respectively (р = 0.017, RR 1.64, 95%CI 1.11–2.42). The effect of silymarin was different in groups of high and low individual risk of drug-induced liver injury defined by validated risk assessment scale. Only in patients with high individual risk the rate of drug-induced injury in silymarin group was significantly low: 23.2% (13/56) vs 65.8% (25/38) in control group (р < 0.001, RR = 2.83, 95%CI 1.67–4.81). In patients with low individual risk silymarin had no protective effect (19.2% and 12.8% cases of druginduced injury in silymarin and control groups, p = 0,320). So, silymarin preventive use indicated only for TB patients with high individual risk of drug-induced liver injury.
About the Authors
D. A. Ivanova
ГБУЗ города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
Д. Кудлай
ФГБОУ ДПО «Институт повышения квалификации» ФМБА России
Russian Federation
Russian Federation
S. E. Borisov
ГБУЗ города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
Н. Николенко
ГБУЗ города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Ерохин В.В., Панасек И.А., Адамович Н.В. Клинико-морфологические критерии лекарственного гепатита у больных туберкулезом легких // Проблемы туберкулеза. – 1991. – № 1. – С. 35-41.
2. Иванова Д.А., Борисов С.Е. Оценка риска и мониторинг гепатотоксических реакций у больных туберкулезом // Туберкулез и болезни легких. – 2017. – Т. 95. – № 9. – С. 40-48.
3. Лечение туберкулеза: рекомендации. – 4-е изд. – ВОЗ: Европейское Региональное бюро ВОЗ, 2011. – 183 с.
4. Матвеев А.В. Гепатопротекторы. Анализ международных исследований по препаратам группы лекарств для печени. – Симферополь: ИТ «Ариал», 2013. – 384 с.
5. О совершенствовании противотуберкулезных мероприятий в Российской Федерации: приказ Минздрава России № 109 от 21 марта 2003 г. – М.: МАИ, 2003. – 347 с.
6. Agal S., Baijal R., Pramanik S. et al. Monitoring and management of antituberculosis drug induced hepatotoxicity // J. Gastroenterol. Hepatol. – 2005. – Vol. 20. – P. 1745-1752.
7. Aithal G.P., Watkins P.B., Andrade R.J. et al. Case definition and phenotype standardization in drug-induced liver injury // Clin. Pharmacol. Ther. – 2011. – N. 89. – Р. 806-815.
8. Ambreen K., Sharma R., Singh K.P., Kumar S. Anti-tuberculosis drug-induced hepatotoxicity: a review// Int. J. Adv. Biotechn. Res. – 2014. – Vol. 5. – N. 3. – P. 423-37.
9. Eminzade S., Uraz F., Izzettin F.V. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals // Nutr. Metab. (Lond). – 2008. – Vol. 5. – N. 5. – P. 18.
10. Gu J., Tang S.-J., Tan S.-Y. et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury // Int. J. Clin. Experiment. Med. – 2015. – Vol. 8. – N. 3. – P. 4320-4327.
11. Liu Q., Garner P., Wang Y. et al. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies // BMC Public Health. – 2008. – Vol. 8. – P. 365.
12. Luangchosiri C., Thakkinstian A., Chitphuk S. et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury // BMC Complementary and Alternative Medicine. – 2015. – Vol. 15. – P. 334.
13. Marjani M., Baghaei P., Kazempour Dizaji M. et al. Evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: a randomized clinical trial // Iranian J. Pharmaceutical Research. – 2016. – Vol. 15. – N. 1. – P. 247-252.
14. Maryam S., Bhatti A.S.A., Shahzad A. Protective effects of silymarin in isoniazid induced hepatotoxicity in rabbits // Ann. King Edward Med. Uni. – 2010. – N. 16. – P. 43-47.
15. Nagayama N., Masuda K., Baba M. et al. Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin // Kekkaku. – 2003. – Vol. 78. – N. 4. – P. 339-346.
16. Ramappa V., Aithal G. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management // J. Clin. Experimental Hepatology. – 2012. – Vol. 3. – N. 1. – Р. 37-49.
17. Saukkonen J.J., Cohn D.L., Jasmer R.M. at al. An official ATS Statement: hepatotoxicity of antituberculosis therapy // Am. J. Respir. Crit. Care Med. – 2006. – Vol. 174. – P. 935-52.
18. Wu J.-W., Tsai T.H. Effect of silibinin on the pharmacokinetics of pyrazinamide and pyrazinoic acid in rats // Drug Metabolism and Disposition. – 2007. – Vol. 35. – N. 9. – P. 1603-1610.
19. Wu S., Xia Y., Lu X. et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients // J. Gastroenterol. Hepatol. – 2015. – Vol. 30. – N. 3. – P. 540-545.
20. Zhang S., Pan H., Peng X. et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial // J. Gastroenterol. Hepatol. – 2016. – Vol. 31. – N. 2. – P. 409-416.
Review
For citations:
Ivanova D.A., , Borisov S.E., Effect of silymarin for the prevention of drug-induced liver injury in tuberculosis patients. Tuberculosis and socially significant diseases. 2017;(4):28-33. (In Russ.)
Views:
25
Email this article 